Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

REMAP-CAP (tocilizumab)
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif
  • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
  • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
Talaschian
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
    Veiga
     
    NCT04403685
    RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    65/64 safety concern
    • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
    • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    CORIMUNO-TOCI-1 (Group 1)
     
    NCT04331808
    RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
    64/67 inconclusive
      CORIMUNO-TOCI-ICU (Group 2)
       
      NCT04331808
      RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
      49/43 inconclusive
        1 study excluded by filtering options (1 RCT / 0 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).